Novavax Valuation Multiples

Novavax Overview

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Founded

1987

HQ

Employees

952

Website

novavax.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $952M

EBITDA: $375M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Novavax Financials

Novavax reported last 12-month revenue of $952M and EBITDA of $375M.

In the same LTM period, Novavax generated $882M in gross profit, $375M in EBITDA, and $336M in net income.

Novavax P&L

In the most recent fiscal year, Novavax reported revenue of $1B and EBITDA of $492M.

Novavax expects next 12-month revenue of XXX and NTM EBITDA of XXX

Novavax Stock Performance

Novavax has current market cap of $2B, and enterprise value of $1B.

Novavax's stock price is $10.11.

Novavax Valuation Multiples

Novavax trades at 1.2x EV/Revenue multiple, and 3.0x EV/EBITDA.

Novavax Financial Valuation Multiples

As of March 18, 2026, Novavax has market cap of $2B and EV of $1B.

Equity research analysts estimate Novavax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Novavax has a P/E ratio of 4.9x.

Novavax Margins & Growth Rates

Novavax's revenue in the last 12 month declined by (61%).

Novavax's revenue per employee in the last FY averaged $1.0M.

Novavax's rule of 40 is (22%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Novavax's rule of X is (114%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Novavax Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Novavax M&A Activity

Novavax acquired XXX companies to date.

Last acquisition by Novavax was on XXXXXXXX, XXXXX. Novavax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Novavax Investment Activity

Novavax invested in XXX companies to date.

Novavax made its latest investment on XXXXXXXX, XXXXX. Novavax invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).